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the consequent multi-infarct model and (2) the definition 
of dementia, which only partially fits the numerous clin-
ical phenotypes of VaD.
 The use of brain imaging techniques has revealed that 
VaD is a more complex entity than suggested by the 
multi-infarct model, because the intellectual decline can 
also result from other pathophysiological mechanisms 
which underlie specific neuropathological subgroups. 
VaD may arise from multiple infarcts (multi-infarct de-
mentia, MID), from a single stroke in a location critical 
to mental function (strategic infarct dementia), as well as 
from small-vessel disease. Also in this latter group is ce-
rebral autosomal dominant arteriopathy with subcortical 
infarcts and leukoencephalopathy, a genetically trans-
mitted small-vessel disorder with mutation in the  Notch3 
 gene ( table 1 ). Accordingly VaD, rather than being con-
sidered as a univocal nosological entity, should be regard-
ed as a heterogeneous clinical entity which differs in clin-
ical-pathological phenotype as well as in pathophysiolog-
ical mechanisms, but shares cerebrovascular disease 
(CVD), resulting from vascular or circulatory pathology, 
as the only, or primary, cause of dementia.
 The inadequacy of the multi-infarct model in explain-
ing the complexity of VaD has been further highlighted 
by the recognition of mixed dementia, where VaD coex-
ists with other causes of dementia, particularly Alzhei-
mer’s disease (AD). VaD and AD show a synergic interac-
tion in terms of clinical expression of cognitive impair-
ment  [1] , especially in older people, as well as sharing 
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 Abstract 
 Vascular dementia (VaD), rather than being considered as a 
univocal nosological entity, should be regarded as a hetero-
geneous clinical entity which differs in clinical-pathological 
phenotype as well as in pathophysiological mechanisms, 
but shares cerebrovascular disease (CVD), resulting from vas-
cular or circulatory pathology, as the cause of dementia. The 
aim of this review is to discuss VaD treatment focusing par-
ticularly on more prevalent ischemic forms. Due to the fact 
that there are presently no treatments capable of obtaining 
considerable results once VaD is clinically established, spe-
cific emphasis will be given to the therapeutic strategies 
aimed at the prevention of CVD risk factors. The therapeutic 
strategies aimed at slowing the progression of the disease 
will also be discussed.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 Traditionally, vascular dementia (VaD) has been con-
ceptualized on the basis of two imprecise and misleading 
concepts: (1) the notion of VaD as a result of stroke with 
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common pathogenetic mechanisms  [2, 3] and risk factors 
 [4] . This observation suggests that the reduction of CVD 
risk factors could be effective in preventing VaD and 
AD.
 Another source of uncertainty is the terminology. By 
definition, dementia is a syndrome of acquired intellec-
tual deficit resulting in significant impairment of daily 
functions. This description is fundamentally based on 
the clinical features of AD, the most common cause of 
dementia. The diagnostic criteria for VaD are largely bor-
rowed from those for AD and thus require the presence 
of prominent memory impairment and progressive, ir-
reversible decline, despite the fact that VaD may present 
a different clinical profile, including mild memory defi-
cit, relatively slow progression, and subcortical pattern. 
The concept of VaD is thus shifting towards that of vas-
cular cognitive impairment (VCI), a much broader de-
scription encompassing all forms of cognitive loss due to 
CVD  [5] . In this paper, due to a lack of fully defined di-
agnostic criteria for VCI not derived from those for VaD, 
we will continue to use the term VaD, rather than VCI, 
being aware that the former can be viewed as a subgroup 
of a larger syndrome (i.e. VCI).
 The aim of this review is to discuss VaD treatment, 
focusing particularly on ischemic vascular disease lead-
ing to dementia, as the latter is more prevalent  [6] . Since 
at present there are no treatments capable of obtaining 
considerable results once VaD is clinically established, 
special emphasis will be given to the therapeutic strate-
gies aimed at the prevention of CVD risk factors and at 
slowing the progression of the clinical course.
 Primary Prevention 
 The modest efficacy of the pharmacological treat-
ments of cognitive symptoms once VaD is clinically es-
tablished emphasizes the crucial role of the prevention of 
CVD risk factors in order to avoid the possible appear-
ance of the clinical symptomatology. The formulation of 
any effective preventive strategy depends on the knowl-
edge of the pathophysiological mechanisms. Since CVD 
may be the result of various pathological disorders, strat-
egies for prevention will vary accordingly.
 The principal risk factors for CVD, other than age, 
race and sex, are hypertension, diabetes mellitus, hyper-
cholesterolemia, hyperhomocysteinemia and smoking. 
Although there is no unanimous consent, excessive use 
of alcohol, obesity, and limited physical activity can also 
concur in raising the risk of developing CVD  [7] . Other 
risk factors for CVD are cardioembolic pathologies such 
as atrial fibrillation or mitral valve prolapse. 
 Hypertension 
 The crucial role of hypertension in the development of 
dementia has been confirmed by both cross-sectional  [8] 
Table 1. Synopsis of VaD: nosography, pathophysiology and pathology
Clinical syndromes Mechanisms Types of brain injury Main causes
Multi-infarct dementia Large-vessel thrombotic/embolic 
occlusion
Multiple large cortical/subcortical 
complete infarcts
Atherothrombosis or cardiogenic 
embolism
Strategic infarct dementia Large- or small-vessel occlusion Single strategic cortical/subcortical 
infarct or strategic lacunar infarct
Atherothrombosis or cardiogenic 
embolism
Subcortical ischemic dementia
Lacunar dementia Small-vessel occlusion Multiple subcortical lacunar infarcts Hypertensive/arteriosclerotic angiopathy
Binswanger’s disease1 Hypoperfusion with partial small 
vessel occlusion
Periventricular leukoencephalopathy Hypertensive/arteriosclerotic angiopathy
CADASIL Partial/complete small-vessel 
occlusion
Multiple subcortical lacunar infarcts, 
periventricular leukoencephalopathy
Mutation of Notch3 gene
Ischemic-hypoxic dementia 
(hypoperfusive)
Anoxic-ischemic episode Focal or diffuse white matter lesions Cardiac arrest/surgery, severe 
atherothrombotic stenosis/occlusion
Hemorrhagic dementia Multiple hemorrhagic episodes Deep cerebral hematomas Hypertension
CADASIL = Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.
1 Or subcortical arteriosclerotic leukoencephalopathy.
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and longitudinal studies of appropriate dimension such 
as Uppsala  [9] , HAAS  [10] , Framingham Hearts Study 
 [11] , and ARIC  [12] . More specifically: a relatively high 
diastolic blood pressure ( 6 75 vs.  ^  70 mm Hg) at age 50 
 [13] , a persistently elevated systolic blood pressure in 
midlife  [13] , or stage two hypertension ( 6 160 mm Hg 
systolic and  6 95 mm Hg diastolic) between ages 59 and 
71  [14] , consistently predicted worse cognitive perfor-
mance or, most importantly, white matter lesions at ages 
ranging from 63  [14] to 79 years  [13] .
 Several large, randomized, placebo-controlled trials 
have been conducted to establish whether the treatment 
of hypertension can reduce the risk of developing cogni-
tive impairment. The Systolic Hypertension in the Elder-
ly Program (SHEP)  [15] showed that treatment with the 
diuretic chlorthalidone and/or the   -blocker atenolol 
lowered the risk of stroke, but had no effect on the inci-
dence of dementia. However, differential dropout could 
have biased the cognitive evaluation. The Systolic Hyper-
tension in Europe (Syst-Eur and Syst-Eur 2) Study  [16, 17] 
demonstrated that treatment of isolated systolic hyper-
tension in subjects over the age of 60 with a calcium chan-
nel blocker (nitrendipine) with or without an ACE in-
hibitor (enalapril) and a diuretic (hydrochlorothiazide) 
lowered the rate of development of dementia (AD, VaD 
and mixed) by 55%. These results indicate that treatment 
of 1,000 patients for 5 years prevents 20 cases of dementia 
(95% CI, 7–33). The Perindopril Protection Against Re-
current Stroke Study (PROGRESS)  [18] found that the 
treatment of hypertension with an ACE inhibitor (perin-
dopril) was associated with a 34% reduction of dementia 
in patients with recurrent stroke, but not in absence of 
stroke. The association of the ACE inhibitors with the 
diuretic indapamide was more effective in reducing the 
risk of dementia. Very interestingly, this study has also 
evidenced that the treatment was effective only in pa-
tients without cognitive impairment at baseline. In the 
substudy of the PROGRESS trial (PROGRESS MRI sub-
study), the ability of blood pressure lowering to influence 
white matter hyperintensity was addressed. The authors 
showed that in the group who received active treatment, 
white matter hyperintensity was stopped or delayed  [19] . 
This effect remained after adjustment of several variables 
such as age, gender or stroke type.
 The opportunity of lowering blood pressure in the 
very elderly was addressed by the Study on Cognition and 
Prognosis in the Elderly (SCOPE)  [20] . This study of al-
most 5,000 patients aged 70–89, who randomly received 
angiotensin receptor antagonist (candesartan) or place-
bo, showed only a trend in the risk reduction of dementia. 
However, the lack of evident benefits could be attributed 
to the small difference in blood pressure observed be-
tween the treated group and the placebo group. More-
over, to evaluate cognitive impairment, the Mini Mental 
State Examination was used, whose inability to detect 
cognitive decline in nondemented subjects is well known. 
The optimum values of systolic and diastolic blood pres-
sure are still open to debate. The Hypertension Optimal 
Treatment (HOT) study  [21] suggests that the best pro-
phylactic results are obtained with systolic and diastolic 
values lower than 142 and 80 mm Hg, respectively.
 Collectively, these studies have reached encouraging 
results, suggesting differences among the various classes 
of drugs tested. ACE inhibitors, used with or without di-
uretics, reduce the risk of cognitive decline  [19] and of 
post-stroke dementia, but dementia in absence of stroke 
was not reduced. Calcium antagonists have been report-
ed to remarkably reduce the risk of developing both AD 
and VaD  [17, 18] .   -Blockers, with or without diuretics, 
have not shown any influence on cognitive impairment 
 [16] . None of these studies have been aimed at identifying 
a possible mechanism of dementia prevention. 
 Hypercholesterolemia 
 Hypercholesterolemia is a less significant risk factor 
for stroke than for coronary heart disease. Most of the 
available data have been deduced from trials designed to 
verify the effects of high cholesterol on heart disease. A 
meta-analysis of 45 prospective cohorts counting 450,000 
patients failed to show any correlation between choles-
terol and stroke in the 13,000 cases of ictus observed dur-
ing the follow-up  [22] . Numerous randomized, placebo-
controlled, double-blind trials such as 4S  [23] , CARE  [24] , 
LIPID  [25] , HPS  [26] , PROSPER  [27] , ALLHAT  [28] , KLIS 
 [29] , and GREACE  [30] that focused on the efficacy of 
statins in stroke prevention have been conducted. These 
trials with a combined total of 70,020 subjects with estab-
lished or high risk for coronary heart disease have shown 
a reduction of relative or absolute risk of 21 and 0.9%, re-
spectively. However, it should be noted that the PROSPER 
trials failed to show any effect of the therapy. Regarding 
these results, it should be observed that the absolute risk 
reduction with statins is only modest as compared to 
1.73% of the antiplatelet therapy and 1.7% of the antihy-
pertensive therapy  [31] . Finally, a recent meta-analysis 
showed a 21% reduction in the rate of major vascular 
events, including a 17% reduction in fatal and nonfatal 
stroke with a 12% proportional reduction in all-cause 
mortality per mmol/l reduction in low-density lipopro-
tein cholesterol  [32] . 
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 The data on the effect of statins on VaD are scarce and 
conflicting. There is evidence suggesting that these drugs 
may protect against dementia  [33] , but contrasting results 
were shown by Rea et al.  [34] . However, recent observa-
tions offer an interesting prospect for use of statins in 
preventing AD  [35] . Two extensive retrospective studies, 
a cross-sectional analysis and a case-control study, indi-
cated that patients undergoing statin treatment had a sta-
tistically significantly lower incidence of AD  [36, 37] . 
What mechanisms of action are involved is still unclear. 
Likely, this effect is not linked to the drug’s ability to low-
er cholesterol since it is recognizable only with lovastatin 
and pravastatin, but not with simvastatin  [36] . A possible 
explanation might be found in ApoE and   -amyloid me-
tabolism. Animal studies have shown that statins are able 
to suppress ApoE secretion that in turn reduces plaque 
load and improves cognitive function  [38] . Fassbender et 
al.  [39] demonstrated that simvastatin inhibited   -secre-
tase, which is in accordance with the observation by Ko-
jro et al.  [40] that statins may favor the nonamyloidogen-
ic pathway through   -secretase stimulation. Considering 
the high incidence of mixed dementia, where both com-
ponents (vascular and degenerative) coexist, prospective 
studies assessing the effects of statins on the risk of de-
mentia are to be encouraged.
 Diabetes 
 Diabetes is another risk factor for stroke and VaD. Di-
abetic patients have twice the risk of developing cognitive 
impairment  [41] . A possible mechanism is the impaired 
brain perfusion due to endothelial oxidative damage, and 
alteration of the blood-brain barrier resulting from ex-
cessive glycosylation  [42] . Diabetic patients also present 
high blood viscosity, which is, according to Poiseuille’s 
law, a blood flow-reducing factor. Although it has never 
been strictly shown that controlling blood sugar levels 
can reduce the risk of CVD, the evidence of its beneficial 
effect on diabetic retinal disease allows to assume a sim-
ilar beneficial effect on small cerebral arteries. On the 
other hand, visible changes of retinopathy have been in-
dependently associated with poorer cognitive function 
 [43] . Two nonrandomized studies suggested that im-
proved glycemic control improves cognitive function 
 [44] . 
 Concerning the possible effects of coexistence of both 
hypertension and diabetes risk factors, the ARIC study, 
which recruited 10,963 patients, showed that those with 
hypertension (32.4%) as well as diabetes developed a 
greater deficit in attention span, memory, and executive 
skills in the 6-year follow-up as compared to patients 
without hypertension  [14] . A further study of 3,577 dia-
betic patients over 55 with at least one other risk factor 
for CVD and treated for 4.5 years has shown that the ACE 
inhibitor ramipril (10 mg/day) is able to reduce the risk of 
stroke by 33%  [45] .
 Hyperhomocysteinemia 
 Hyperhomocysteinemia was previously associated 
with VaD in many case-control or cross-sectional studies 
 [46, 47] . Only two prospective studies have examined the 
association between homocysteine and dementia. The 
Framingham Study has shown that homocysteine levels 
over 14   mol/l double the risk of AD and dementia  [48] . 
However, the other study did not replicate this finding 
 [49] . Elevated homocysteinemia can be associated with 
dietary factors limiting intake of folic acid and vitamins 
B 6 and B 12 , or with genetic deficiency of methylenetetra-
hydrofolate reductase. Although in the Nun Study  [50] 
low serum folate was strongly associated with cortical at-
rophy, the evidence does not support a correlation be-
tween serum vitamin B 12 or folate and cognitive impair-
ment in people over 60. Hence, there is little evidence to 
justify treating cognitive impairment with vitamin B 12 or 
folate supplementation  [51] . This is consistent with the 
findings from recent systematic reviews of randomized 
double-blind trials, which have not found any evidence 
of potential benefits from supplementation strategy  [52] .
 Treatment to Contrast Progression 
 Once VaD is clinically established, the therapy is 
aimed primarily at slowing the progression of disease by 
means of secondary prevention.  Although probably less 
common than previously thought, the prevalence of post-
stroke dementia is nearly 20%  [13] . It is important to 
highlight that post-stroke dementia is not a specific en-
tity as it includes cases with multiple corticosubcortical 
infarcts, strategic infarcts, subcortical ischemic VaD and 
AD. Evidence suggests heterogeneity of the underlying 
pathogenic mechanisms; nevertheless, prevention of 
stroke recurrence is mandatory in order to reduce the risk 
of developing dementia. Pharmacological treatments 
aimed at reducing the number of relapses after the first 
stroke are well established  [53] and include carotid end-
arterectomy, warfarin for atrial fibrillation, blood pres-
sure lowering, and, above all, antithrombotic drugs.
 With regard to antiplatelet drugs, their efficacy in sec-
ondary stroke prevention is largely demonstrated. In 
stroke patients, the risk reduction of cerebral ischemic 
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events with aspirin is 20–30%  [54] . The Ticlopidine-As-
pirin Stroke Study  [55] showed slightly more efficacy of 
ticlopidine as compared to aspirin in preventing nonfatal 
stroke or death (6.3 vs. 10.8%). However, ticlopidine has 
been shown to cause neutropenia in 2.4% of treated indi-
viduals. Finally, clopidogrel, a drug similar to ticlopidine 
but with a higher antiplatelet effect, has been compared 
to aspirin in the CAPRIE (Clopidogrel vs. Aspirin in Pa-
tients at Risk of Ischemic Events) study  [56] . The results 
of this trial suggest an overall relative risk reduction for 
stroke of 7.3% in favor of clopidogrel. Most importantly, 
the risk of neutropenia was comparable to that of aspirin. 
However, at the moment, the possibility that prevention 
of recurrent stroke is able to prevent cognitive decline is 
still open to debate, but as the reduction of stroke plays a 
key role in decreasing the risk of dementia (both VaD and 
mixed dementia), it can be inferred that antiplatelet drugs 
probably reduce the risk of cognitive decline. Although 
the efficacy of antithrombotic therapy in stroke preven-
tion is well documented, the role of this approach in pre-
venting cognitive decline is still to be proved. A large pro-
spective study (3,809 subjects over the age of 65) over 3 
and 6 years failed to show any statistically significant ef-
fect of aspirin in preventing any form of dementia  [57] . 
Two other studies  [58, 59] showed that the antithrom-
botic agents (aspirin, warfarin or a combination of both) 
may prevent cognitive decline. 
 A comment on the specific management of hyperten-
sion has to be made. The strong association between sub-
cortical ischemic VaD and hypertension suggests that 
control of hypertension may be particularly important in 
preventing progression. On the other hand, treatment re-
quires great caution, especially in elderly patients. Chron-
ically hypertensive patients have a shifted autoregulatory 
range for cerebral blood flow to accommodate higher 
perfusion pressures. Thus, these patients are easily sus-
ceptible to hypotension, even at otherwise normal pres-
sure. This may be important, as periodic hypotension is 
a suggested mechanism for white matter changes ob-
served in these patients. Voko et al.  [60] have shown that 
there is an increased risk of stroke when diastolic pres-
sure drops below 65 mm Hg.
 Conclusions and Future Directions 
 Once VaD is clinically established no really effective 
treatment is currently available; consequently, a thera-
peutic approach based on prevention is strongly recom-
mended. Nevertheless, while the association of coronary 
heart disease and stroke with risk factors such as hyper-
tension, diabetes mellitus, hypercholesterolemia, and hy-
perhomocysteinemia is well recognized, a definite rela-
tionship of these factors with dementia remains to be es-
tablished. For instance, with regard to hypertension many 
studies have been able to show an association with de-
mentia  [9, 10, 11, 12] , but there is a lack of consensus about 
the ability of antihypertensive therapy to prevent demen-
tia  [15, 18] . That cholesterol is an unequivocal risk factor 
for stroke remains to be demonstrated and still less sig-
nificant is its association with dementia. However, con-
sidering the relationship between VaD and AD, an inter-
esting perspective in this field is gained from the observa-
tion of the effects of statins in preventing AD. Similar 
considerations may be proposed concerning diabetes and 
hyperhomocysteinemia.
 The lack of universal agreement may have two main 
causes. The methodological features of the studies, such 
as the neuropsychological tests used and study design 
(cross-sectional vs. longitudinal, observational vs. exper-
imental, sample size, covariances, statistical methodolo-
gies and primary endpoints considered) may contribute 
to such uncertainty. More importantly, a further source 
of complexity arises from the heterogeneity of patho-
physiological mechanisms that underlie the different 
clinical forms of VaD. Accordingly, VaD should be re-
garded as a heterogeneous clinical entity that may require 
a multifaceted preventive approach. Finally and paradox-
ically, the growing evidence that risk factors for CVD are 
also risk factors for AD makes these studies more diffi-
cult to interpret. 
 Based on previous observations, two main targets in 
future clinical trials of VaD prevention should be ad-
dressed: (1) assessing the interdependence between risk 
factors and (2) defining more distinct and homogeneous 
clinical forms to include VaD, mixed dementia and AD. 
Further subgroup analyses for VaD should include, at 
least, subcortical versus cortical forms and small- versus 
large-vessel disease. However, although several questions 
remain unanswered, the prevention of CVD risk factors 
is the most promising approach to VaD.
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